Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G E Plautz

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Adoptive immunotherapy of CNS malignanciesG E Plautz, S Shu
Cellular Immunology|August 1, 1996
Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumorsG E Plautz, M Inoue, S Shu
Cancer Research|October 15, 1996
Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cellsM Inoue, G E Plautz, S Shu
Cellular Immunology|June 15, 1997
Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cellsG E Plautz, J E Touhalisky, S Shu
Annals of the New York Academy of Sciences|April 18, 1994
Recombinant growth factor gene expression in vascular cells in vivoE G Nabel, G E Plautz, G J Nabel
Cancer Research|October 28, 1999
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacyS Mukai, J Kjaergaard, S Shu, et al.
Cancer Research|March 23, 2000
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomasB H Joshi, G E Plautz, R K Puri
Cellular Immunology|March 24, 1999
Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cellsS Mukai, H Kagamu, S Shu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2000
Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumorsG E Plautz, S Mukai, P A Cohen, et al.
JAMA|December 13, 1997
Tumor immunologyS Shu, G E Plautz, J C Krauss, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Adoptive immunotherapy of CNS malignanciesG E Plautz, S Shu
Cellular Immunology|August 1, 1996
Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumorsG E Plautz, M Inoue, S Shu
Cancer Research|October 15, 1996
Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cellsM Inoue, G E Plautz, S Shu
Cellular Immunology|June 15, 1997
Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cellsG E Plautz, J E Touhalisky, S Shu
Annals of the New York Academy of Sciences|April 18, 1994
Recombinant growth factor gene expression in vascular cells in vivoE G Nabel, G E Plautz, G J Nabel
Cancer Research|October 28, 1999
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacyS Mukai, J Kjaergaard, S Shu, et al.
Cancer Research|March 23, 2000
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomasB H Joshi, G E Plautz, R K Puri
Cellular Immunology|March 24, 1999
Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cellsS Mukai, H Kagamu, S Shu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2000
Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumorsG E Plautz, S Mukai, P A Cohen, et al.
JAMA|December 13, 1997
Tumor immunologyS Shu, G E Plautz, J C Krauss, et al.
Pageof 4